Stock Ratings / Health Care / ICCC / forecast

IMDX (27) TKNO (46) NNNN (36) MYGN (46) ⌘ Pro Terminal →

ImmuCell Corporation (ICCC) 12-Month Stock Forecast & Price Target Cone

$10.26 -0.58% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.23

ImmuCell Corporation (ICCC) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $93.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ICCC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ICCC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, ImmuCell Corporation (NASDAQ: ICCC) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $10.26 (-0.58% 1D, market cap $93.7M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, ICCC ranks #190 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ICCC compare to IMDX and TKNO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), ICCC carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of 41.4%, and ROIC of 4.2%. By comparison, IMDX (Insight Molecular Diagnostics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $104.1M) and TKNO (Alpha Teknova Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -21.3%, cap $499.2M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ICCC?

▼

Per ICCC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000811641), ImmuCell Corporation generated $27.6M in revenue (+4.3% YoY), -$1.0M in net income, and $1.2M in free cash flow against $42.5M in total assets and $7.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.23 (-0.29%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 4.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+0.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ICCC)Realized 20D OHLCV Swing Band: ±5%

Deterministic 5-Pillar Attribution (59/100 Composite)

🔍 WHY ICCC SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+16/20 pts (27% of score)

FRED Regime × Technicals: 76% of 52W Range • RSI-14 at 51.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 4.28 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution8/20 pts (-12 pt drag)

Disciplined Float (+1.08% YoY Shares) & executive Form 4 sales trim 12 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$9.60+9.5% Next Q

Q2 (-2Q)

Grade C-$10.51-2.6% Next Q

Q3 (-1Q)

Grade C$10.24+0.2% Next Q

Current

Grade C-$10.26+0.2% Hist 90D α

Trajectory: C- (51) → C- (59)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ICCC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, ICCC faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (+1.08% YoY Shares) — any gross margin slip below 38.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($10.04) or 200D SMA ($8.88) invalidates the momentum regime and cuts Target Base ($10.31) toward Bear Floor ($8.04).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ICCC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ICCC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 59%NO 41%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ICCC Position Size: $10,000

Shares at $10.26: 974.7 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $8.04

$7,836

$-2,164 (-21.6%)

12M Consensus BaseTarget $10.31

$10,049

+$49 (+0.5%)

12M Bull Case BreakoutTarget $12.71

$12,388

+$2,388 (+23.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$11	74%	A
Goldman SachsSector Coverage Lead	BUY	$12	69%	B
JP MorganUS Large-Cap Research	HOLD	$9	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (ICCC Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ICCC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +17.66%📐 WEDGE COMPRESSION COIL

2026-11-02O $10.62H $10.62L $10.26C $10.26VOL 3.3K

RES: $10.77SUP: $9.64SMA50: $10.04SMA200: $8.88

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ICCC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ICCC Butterfly Map → + Track ICCC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

33.5%/yr Implied 5Y Growth

vs. +4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ICCC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ICCC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ICCC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ICCC)

Health Care Rank #190 of 1016 ⚔️ IMDX vs ICCC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ICCC vs. IMDX, TKNO, NNNN, MYGN)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ImmuCell Corporation (ICCC) ranks #190 by composite RQD confidence (59/100, grade C-) and #669 by equity capitalization ($93.7M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. ICCC currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ICCC ACTIVE ImmuCell Corporation	C-	59/100	—	41.4%	4.2%	-0.58%	$93.7M	Benchmark Subject
IMDX Insight Molecular Diagnostics Inc.	E	27/100	—	56.7%	-35.0%	-6.92%	$104.1M	/imdx-vs-iccc →
TKNO Alpha Teknova Inc.	D	46/100	—	33.2%	-21.3%	-9.02%	$499.2M	/tkno-vs-iccc →
NNNN Anbio Biotechnology (Class A)	D-	36/100	83.6x	87.2%	17.0%	-9.68%	$535.3M	/nnnn-vs-iccc →
MYGN Myriad Genetics Inc.	D	46/100	—	69.9%	-35.0%	-4.80%	$638.0M	/mygn-vs-iccc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000811641

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ImmuCell Corporation (ICCC) reported GAAP revenue of $27.6M (+4.3% vs. FY2024 revenue of $26.5M , and +58.2% cumulative change since FY2023) , GAAP net income of -$1.0M, operating cash flow of $2.5M, and free cash flow of $1.2M (+1236.0% YoY). On the balance sheet, ICCC closed FY2025 with $42.5M in total assets against $7.5M in total debt (Altman Z-Score: 4.28, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$27.6M	-$1.0M	$2.5M	$1.2M	$42.5M	$7.5M
FY2024 (FY)	2024-12-31	$26.5M	-$2.2M	$357.9K	-$107.8K	$45.1M	$9.0M
FY2023 (FY)	2023-12-31	$17.5M	-$5.8M	-$4.7M	-$4.7M	—	—

3. ICCC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ICCC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ICCC compare to IMDX and TKNO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ICCC?

Where is ICCC trading relative to its 50-day, 200-day, and 52-week technical levels?

ICCC last traded at $10.26 (-0.58% on volume of 11,025 shares), positioning the stock +2.19% above its 50-day simple moving average ($10.04) and +15.54% above its 200-day simple moving average ($8.88). Across its 52-week range of $4.52 to $12.10, ICCC sits at the 75.7% percentile with a 14-day RSI of 51.8 (NEUTRAL RANGE) and an implied next-earnings move of ±5.0% ($9.75 to $10.77).

ICCC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ICCC's 12-month stock price target?

ImmuCell Corporation (ICCC) carries a 12-month consensus base price target of $10.31 (+0.5% from $10.26), with a bull-case target of $12.71 and a bear-case floor of $8.04.

Is ICCC stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ICCC C- (Hold — HOLD) with an RQD Confidence score of 59/100.

Direct Sub-Reports: ICCC RQD Cockpit ICCC 12M Forecast ICCC Earnings & Move ICCC Dividends & DRIP ICCC Insiders & 13F ICCC Whale Options ICCC Profit Sankey ICCC News & Why

ROARABLE RATING BRIEF • RQD 59/100 (C-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ICCC — ImmuCell Corporation: What the Facts Mean to a Prospective Investor

Engine: Haiku 5.5 Dossier Pipeline

As of: 2026-11-02T14:20Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, ImmuCell Corporation (ICCC) carries a composite score of 59/100 (C- — Roarable Hold — Cautious Neutral) at a current price of $10.26 (-0.58%). Fundamental cash generation scores 11/20 (ROIC 4.2%, FCF yield 1.31%), institutional 13F whale accumulation scores 11/20, insider conviction scores 8/20, macro regime alignment scores 16/20 (Beta 1.00), and forensic balance-sheet protection scores 13/20 (Altman Z-Score 4.28, Piotroski F-Score 8/9).

Investor Implication: At current trailing P/E and current forward P/E within Biotechnology: In Vitro & In Vivo Diagnostic Substances, upside depends on sustained operating margin expansion (6.0%) and free cash flow conversion relative to the 52-week range of $4.52 – $12.10.

Butterfly Effect: Supply-Chain, Sector & Catalyst Ripples

Operating in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), ICCC is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin 41.4%), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).

Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.

ICCC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ImmuCell Corporation (ICCC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ICCC Debate Forum (3) ↓

🟢 CATALYST Yahoo • 11d ago

ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?

Zoetis offers diversification and stability, while ImmuCell boasts stronger sales growth and expansion potential.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 20d ago

ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results

PORTLAND, Maine, Oct. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf he

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 20d ago

ImmuCell Sees Q3 Sales $8.000M

ImmuCell (NASDAQ:ICCC) sees Q3 sales of $8.000 million.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 20d ago

ImmuCell Reports Q3 Preliminary Sales Of $8M, Up 46% YoY

ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity,

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 73d ago

ImmuCell (ICCC) Q2 2026 Earnings Call Transcript

Product sales hit $7.2 million as market share climbed to 19% amid capacity expansion plans.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 79d ago

ImmuCell Corp (ICCC) (Q2 2026) Earnings Call Highlights: Record Net Income and Market Share ...

Yahoo Finance coverage on ICCC stock catalysts, institutional flow, and earnings outlook.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 80d ago

ImmuCell Q2 Earnings Call Highlights

ImmuCell (NASDAQ:ICCC) reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 million to more than trip

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 80d ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026

PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf he

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ICCC Bull vs. Bear Conversation Board — What's Your Call at $10.26?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ICCC 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $11.15 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ICCC (C- • RQD 59/100) a Buy at $10.32?

Welcome to the ICCC (ImmuCell Corporation) Roar Pit. Current RQD Composite is 59/100 (Roarable Hold — Cautious Neutral) in Biotechnology: In Vitro & In Vivo Diagnostic Substances. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $7.84 (-24.0%)

Spot @ $10.32

Pump the brakes on ICCC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ICCC, but look at what you are paying: current EV/EBITDA multiples with 41.4% gross margins. Unless ImmuCell Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $12.59 (+22.0%)

Spot @ $10.32

ICCC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ICCC, the market is fixating on short-term headline noise in Biotechnology: In Vitro & In Vivo Diagnostic Substances and ignoring the balance sheet and cash flow trajectory. At $10.32 (52-wk range $4.52 - $12.10), any beat on forward guidance forces shorts and underweight funds to chase.